Tumor-resident probiotic Clostridium butyricum improves aPD-1 efficacy in colorectal cancer models by inhibiting IL-6-mediated immunosuppression
Mingxu Xie, Kai Yuan, Yongxin Zhang, Yating Zhang, Ruyi Zhang, Jie Gao, Wenchao Wei, Lanping Jiang, Tianhui Li, Yanqiang Ding, Luyao Wang, Yufeng Lin, Chi Chun Wong, Jun Yu
Abstract
humanized mice and autologous patient-derived CRC organoids-CTLs co-culture system. To summarize, C. butyricum is a promising adjuvant to augment ICB therapy.
Topics & Concepts
Clostridium butyricumCancer researchColorectal cancerCD8Cytotoxic T cellT cellPI3K/AKT/mTOR pathwayImmunotherapyImmune systemMedicineImmunologyBiologyCancerSignal transductionInternal medicineBacteriaGeneticsBiochemistryIn vitroImmune cells in cancerGut microbiota and healthCancer Immunotherapy and Biomarkers